GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,651.00GBp
11:35am EDT
Price Change (% chg)

8.50p (+0.52%)
Prev Close
1,642.50p
Open
1,652.00p
Day's High
1,660.00p
Day's Low
1,640.00p
Volume
6,766,966
Avg. Vol
8,242,283
52-wk High
1,816.00p
52-wk Low
1,528.00p

GSK.L

Chart for GSK.L

About

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in... (more)

Overall

Beta: 0.47
Market Cap (Mil.): £79,813.84
Shares Outstanding (Mil.): 4,859.29
Dividend: 23.00
Yield (%): 4.75

Financials

  GSK.L Industry Sector
P/E (TTM): 14.78 33.36 33.52
EPS (TTM): 1.11 -- --
ROI: 20.72 19.69 18.94
ROE: 84.96 20.38 19.71
Search Stocks

Exclusive: Marubeni says Chinese authorities detain three staff at grain unit

TOKYO/BEIJING - Three employees at one of Marubeni Corp's grain trading units in China have been detained by authorities, the Japanese trading house said on Thursday, a move sources told Reuters was prompted by allegations the unit evaded taxes on soy bean imports.

23 Apr 2014

Novartis-GSK asset swap offers template for pharma and beyond

LONDON - The loud welcome given by investors to this week's deal for Novartis and GlaxoSmithKline to trade more than $20 billion of assets could trigger more pacts in the pharmaceuticals sector and beyond.

23 Apr 2014

Novartis-GSK asset swap offers template for pharma and beyond

LONDON, April 23 - The loud welcome given by investors to this week's deal for Novartis and GlaxoSmithKline to trade more than $20 billion of assets could trigger more pacts in the pharmaceuticals sector and beyond.

23 Apr 2014

RPT-Fitch: Novartis/GSK Deal Highlights Narrowing R&D Focus

April 23 - (The following statement was released by the rating agency)

23 Apr 2014

PRESS DIGEST- New York Times business news - April 23

April 23 - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy.

23 Apr 2014

Novartis and GSK trade assets as pharma industry reshapes

ZURICH/LONDON - Novartis and GlaxoSmithKline agreed to trade more than $20 billion worth of assets on Tuesday to bolster their best businesses and exit weaker ones as the drug industry contends with healthcare spending cuts and generic competition. | Video

22 Apr 2014

UPDATE 4-Novartis and GSK trade assets as pharma industry reshapes

* Deals, plus talk of Pfizer-Astra deal, lift sector shares (Adds details on Lilly animal health unit, updates share movement)

22 Apr 2014

M&A in pharmaceuticals helps European shares extend rally

* Indexes extend gains after strong consumer confidence data

22 Apr 2014

Deals and deal talk among pharmaceuticals lift Britain's FTSE

* FTSE 100 gains 0.9 pct * AstraZeneca surges on report of Pfizer approach * GlaxoSmithKline jumps on asset swap with Novartis (Updates with closing prices, adds technical detail) By Alistair Smout LONDON, April 22 - Corporate activity in the pharmaceutical sector on Tuesday pushed Britain's benchmark stock index to a two-week high and to within sight of a peak for this year. Drugmaker AstraZeneca rose 4.7 percent, with trading volumes in the stock more than three

22 Apr 2014

M&A activity in pharmaceuticals pushes UK's FTSE higher

* FTSE 100 up 1.1 pct * AstraZeneca surges on reported Pfizer bid interest * GlaxoSmithKline jumps on asset swap with Novartis (Adds detail, quote, updates prices) By Alistair Smout LONDON, April 22 - Merger and acquisition activity among drug companies drove Britain's top share index to a two-week high on Tuesday, putting it within sight of its peak for 2014. Drugmaker AstraZeneca surged 6.7 percent, with trading volumes in the stock over twice its 90-day average

22 Apr 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks